Charles River Laboratories International (CRL) Stock Forecast & Price Target

$162.93 -2.07 (-1.26%)

As of 02:11 PM Eastern

Charles River Laboratories International - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Reduce

Based on 16 Analyst Ratings

Sell
3

Hold
12

Buy
1

Based on 16 Wall Street analysts who have issued ratings for Charles River Laboratories International in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 16 analysts, 3 have given a sell rating, 12 have given a hold rating, and 1 has given a buy rating for CRL.

Consensus Price Target

$195.71
20.12% Upside

According to the 16 analysts' twelve-month price targets for Charles River Laboratories International, the average price target is $195.71. The highest price target for CRL is $290.00, while the lowest price target for CRL is $151.00. The average price target represents a forecasted upside of 20.12% from the current price of $162.93.

Get the Latest News and Ratings for CRL and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Charles River Laboratories International and its competitors.

CRL Analyst Ratings Over Time

Type	Current Forecast 2/21/24 to 2/20/25	1 Month Ago 1/22/24 to 1/21/25	3 Months Ago 11/23/23 to 11/22/24	1 Year Ago 2/21/23 to 2/21/24
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	2 Buy rating(s)	2 Buy rating(s)	7 Buy rating(s)
Hold	12 Hold rating(s)	11 Hold rating(s)	10 Hold rating(s)	5 Hold rating(s)
Sell	3 Sell rating(s)	3 Sell rating(s)	3 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$195.71	$209.00	$214.38	$246.54
Forecasted Upside	20.12% Upside	23.06% Upside	9.51% Upside	2.26% Upside
Consensus Rating	Reduce	Reduce	Reduce	Moderate Buy

CRL Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

CRL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Charles River Laboratories International Stock vs. The Competition

Type	Charles River Laboratories International	Medical Companies	S&P 500
Consensus Rating Score	1.88	2.82	2.53
Consensus Rating	Reduce	Moderate Buy	Moderate Buy
Predicted Upside	20.12% Upside	28,299.98% Upside	13.18% Upside
News Sentiment Rating	Positive News See Recent CRL News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
2/20/2025	JPMorgan Chase & Co. 3 of 5 stars	Casey Woodring Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$175.00 ➝ $165.00	+0.06%
2/20/2025	Robert W. Baird 2 of 5 stars	Eric Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Neutral ➝ Neutral	$177.00 ➝ $173.00	+4.85%
2/18/2025	Barclays 3 of 5 stars	Luke Sergott Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$205.00 ➝ $166.00	+9.16%
2/5/2025	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Ricky Goldwasser Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Equal Weight ➝ Equal Weight	$220.00 ➝ $184.00	+12.92%
1/23/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Matthew Sykes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	Buy ➝ Buy	$220.00 ➝ $190.00	+14.88%
1/22/2025	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Max Smock Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
1/17/2025	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Dan Leonard Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$250.00 ➝ $185.00	+11.72%
12/13/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$220.00 ➝ $210.00	+9.87%
11/18/2024	CLSA Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Hold ➝ Underperform	$164.00	-12.65%
11/11/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Hold ➝ Hold	$203.00 ➝ $227.00	+2.93%
Get the Latest News and Ratings for CRL and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Charles River Laboratories International and its competitors with MarketBeat's FREE daily newsletter.
11/7/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Anderson Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	In-Line ➝ In-Line	$190.00 ➝ $225.00	+5.02%
10/14/2024	Redburn Atlantic Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sell	$151.00	-20.97%
10/1/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	P. Donnelly Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell	$215.00 ➝ $175.00	-11.15%
8/8/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	E. Coldwell Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/28/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Toung Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
6/7/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	A. Hynes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$235.00	+6.04%
2/15/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Neutral
9/22/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$280.00 ➝ $275.00	+38.78%
5/12/2023	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$260.00 ➝ $250.00	+31.01%
5/12/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$260.00 ➝ $255.00	+30.27%
3/28/2023	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold	$233.00 ➝ $203.00	+2.81%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 02:11 PM ET.

CRL Forecast - Frequently Asked Questions

: According to the research reports of 16 Wall Street equities research analysts, the average twelve-month stock price forecast for Charles River Laboratories International is $195.71, with a high forecast of $290.00 and a low forecast of $151.00.
: 16 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Charles River Laboratories International in the last twelve months. There are currently 3 sell ratings, 12 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "reduce" CRL shares.
: According to analysts, Charles River Laboratories International's stock has a predicted upside of 20.12% based on their 12-month stock forecasts.
: Over the previous 90 days, Charles River Laboratories International's stock had 1 downgrade by analysts.
: Charles River Laboratories International has been rated by research analysts at Bank of America, Barclays, JPMorgan Chase & Co., Morgan Stanley, Robert W. Baird, The Goldman Sachs Group, UBS Group, and William Blair in the past 90 days.
: Analysts like Charles River Laboratories International less than other "medical" companies. The consensus rating for Charles River Laboratories International is Reduce while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how CRL compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top-Rated Stocks

More Ratings Tools

This page (NYSE:CRL) was last updated on 2/20/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Charles River Laboratories International (CRL) Stock Forecast & Price Target